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Skeletal myosin binding protein-C 
isoforms regulate thin filament 
activity in a Ca2+-dependent 
manner
Brian Leei Lin1, Amy Li2,3, Ji Young Mun4,6, Michael J. Previs2, Samantha Beck Previs2,  
Stuart G. Campbell5, Cristobal G. dos Remedios3, Pieter de P. Tombe1, Roger Craig4,  
David M. Warshaw2 & Sakthivel Sadayappan  1
Muscle contraction, which is initiated by Ca2+, results in precise sliding of myosin-based thick and 
actin-based thin filament contractile proteins. The interactions between myosin and actin are finely 
tuned by three isoforms of myosin binding protein-C (MyBP-C): slow-skeletal, fast-skeletal, and cardiac 
(ssMyBP-C, fsMyBP-C and cMyBP-C, respectively), each with distinct N-terminal regulatory regions. 
The skeletal MyBP-C isoforms are conditionally coexpressed in cardiac muscle, but little is known about 
their function. Therefore, to characterize the functional differences and regulatory mechanisms among 
these three isoforms, we expressed recombinant N-terminal fragments and examined their effect 
on contractile properties in biophysical assays. Addition of the fragments to in vitro motility assays 
demonstrated that ssMyBP-C and cMyBP-C activate thin filament sliding at low Ca2+. Corresponding 3D 
electron microscopy reconstructions of native thin filaments suggest that graded shifts of tropomyosin 
on actin are responsible for this activation (cardiac > slow-skeletal > fast-skeletal). Conversely, at 
higher Ca2+, addition of fsMyBP-C and cMyBP-C fragments reduced sliding velocities in the in vitro 
motility assays and increased force production in cardiac muscle fibers. We conclude that due to the 
high frequency of Ca2+ cycling in cardiac muscle, cardiac MyBP-C may play dual roles at both low and 
high Ca2+. However, skeletal MyBP-C isoforms may be tuned to meet the needs of specific skeletal 
muscles.
Myosin binding protein-C (MyBP-C) is a striated muscle protein that regulates contraction and consists of three 
isoforms known as slow-skeletal, fast-skeletal, and cardiac (ssMyBP-C, fsMyBP-C, and cMyBP-C), encoded by 
MYBPC1, MYBPC2 and MYBPC3, respectively1–3. As their names would suggest, ssMyBP-C and fsMyBP-C are 
predominantly expressed in adult skeletal muscle tissue, while cMyBP-C is the predominant isoform in the heart4. 
However, the naming convention belies the complex expression of MyBP-C isoforms, as studies have demon-
strated that ssMyBP-C is expressed at low levels in the mammalian atrium5, and fsMyBP-C is present in the 
heart in murine models of heart failure6. Few studies exist on ssMyBP-C4, with fewer still on fsMyBP-C7. As 
such, their individual contributions to contractile regulation are essentially unknown. The clinical significance 
of understanding the function of each isoform is clear: mutations in cMyBP-C are the most common cause of 
hypertrophic cardiomyopathy (HCM)8, while more recently, mutations in ssMyBP-C and fsMyBP-C that cause 
skeletal muscle myopathies, such as distal arthrogryposis, have been discovered9–11.
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cMyBP-C is the best-characterized isoform, and its N-terminal region regulates contractility through its inter-
action with both myosin subfragment 2 (S2) and actin12–14. Myosin and actin are the major thick and thin filament 
proteins that interact to produce filament sliding at the molecular level. Interestingly, the cMyBP-C N-terminal 
regulatory region activates the thin filament by shifting the position of tropomyosin (Tm) from a “blocked” 
position to a “closed” position13, exposing myosin-binding sites on F-actin. Shifting Tm is the same mechanism 
by which Ca2+ and the troponin complex (Tn) activate the thin filament to enable contraction15. However, Tm 
shift by Tn and MyBP-C are not redundant mechanisms. The centralized location of MyBP-C within the sar-
comere appears critical for the correction of an inhomogeneity in activation resulting from a spatiotemporal 
Ca2+ gradient16. What seems redundant is the presence of three distinct MyBP-C isoforms that are conditionally 
co-expressed. However, each MyBP-C isoform is structurally unique, and as our data show, functionally unique.
All MyBP-C isoforms consist of a linear array of seven immunoglobulin-like and three fibronectin-like 
domains numbered C1 to C10, as well as unique N-terminal structures: an M-domain between C1 and C217 
and a proline/alanine-rich (PA) sequence preceding the C1 domain (Fig. 1A). Critically important differences 
exist within the N-terminal region up to the C2 domain (Fig. 1A, dotted box). For example, cMyBP-C has a 
Figure 1. Regulation of muscle contraction by MyBP-C isoforms was determined using recombinant 
proteins representing the N-terminal region of slow-skeletal, fast-skeletal, and cardiac isoforms of MyBP-C. 
(A) Schematic diagram of full-length slow-skeletal, fast-skeletal, and cardiac MyBP-C isoforms (ssMyBP-C, 
fsMyBP-C, and cMyBP-C, respectively). Domains are numbered C0 to C10 from the N-terminus, and proline-
alanine region (PA) is common to all isoforms. Circles denote immunoglobulin-like domains, and pentagons 
represent fibronectin type 3 domains. Yellow lines identify known phosphorylation sites; red lines indicate 
cardiac-specific insert in C5 domain of cMyBP-C. (B) SDS-PAGE demonstrates the relative size and purity 
of each MyBP-C recombinant protein, encompassing the N-terminal region, up to and including the C2 
domain. (C–F) Permeabilized ventricular rat papillary muscles were left untreated (control, white column) or 
were incubated with 10 µM ssC1C2 (red), fsC1C2 (blue), and C0C2 (black) and allowed to undergo muscle 
contraction analysis by the Force-ATPase assay. (C) Relative force-pCa curves and (D) quantification of pCa50 
values from the relative force-pCa curves demonstrate significant increases of fsC1C2 and C0C2 in Ca2+-
sensitivity of force development. (E) Rate of tension redevelopment (ktr) was determined using a rapid release 
and restretch maneuver at maximal Ca2+ levels (pCa 4.5) and submaximal Ca2+ levels (pCa 6). Top trace is 
of (F) at pCa 6, and ktr was significantly enhanced by fsC1C2 and C0C2. Graphs represented as mean ± SEM, 
*p < 0.05 vs. controls, **p < 0.01 vs. controls, #p < 0.05 vs. ssC1C2/fsC1C2, n = 7–9 animals.
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cardiac-specific IgG domain (C0) at its N-terminus that binds myosin regulatory light chain (MLC2) and actin in 
vitro18. cMyBP-C also has four phosphorylation sites in its M domain19 and one more in its PA region20. In con-
trast, the ssMyBP-C isoform has only one phosphorylation site in its M domain and three in its PA region21 and 
no known phosphorylation sites have been found in fsMyBP-C. Sequence comparisons within this region suggest 
unique N-terminal structural differences (Supplemental Table S1), prompting us to determine the impact of the 
three major MyBP-C isoforms on muscle contractility, with a focus on heart muscle.
Our objective is to parse out the differences among the N-terminal regulatory regions (up to and including 
the C2 domain) of each individual MyBP-C isoform (Fig. 1A and Supplemental Table S1). How these isoforms 
vary in their interactions with the thin filament may explain why three distinct isoforms are expressed, and the 
answers may lay the groundwork for future studies in the skeletal MyBP-C field. Thus, we generated recombinant 
N-terminal peptides of ssMyBP-C, fsMyBP-C and cMyBP-C (ssC1C2, fsC1C2, and C0C2, respectively) and char-
acterized their functions using a wide combination of biophysical techniques. We used three-dimensional recon-
structions of electron microscopy images, measurements of fiber force-ATPase activity, in vitro motility assays, 
cardiomyocyte unloaded shortening, and computer simulation approaches to determine how these N-terminal 
fragments affect muscle function. Overall, our studies demonstrate that ssMyBP-C and cMyBP-C share simi-
lar regulatory function at low Ca2+. Conversely, fsMyBP-C and cMyBP-C share similar regulatory function at 
higher Ca2+. Steady-state functional experiments demonstrate that all MyBP-C isoforms sensitize the thin fila-
ments to Ca2+ and that the extent of sensitization is isoform-specific. Structural studies demonstrate that each 
isoform affects tropomyosin position on F-actin, which, in turn, may regulate function in a graded manner. 
Lastly, dynamic functional experiments, which measured in vitro and in silico unloaded myocyte shortening, 
confirmed our principal expectation22: that the greater capacity to activate the thin filament results in slower 
relaxation kinetics. Our results suggest that cMyBP-C has distinct regulatory functions over a full range of Ca2+, 
possibly because of the dynamic range of intracellular Ca2+ experienced on a beat-to-beat basis in the heart. 
Conversely, differential expression of ssMyBP-C and fsMyBP-C in skeletal muscles may have evolved to fine-tune 
the role of skeletal MyBP-C in fast-twitch and slow-twitch muscles. The relatively small amounts of ssMyBP-C 
and fsMyBP-C expressed in the heart may also subtly augment cardiac muscle function. Taken together, these 
data are the first to reveal differences in the underlying molecular and cellular regulatory functionality of all three 
MyBP-C N-termini.
Results
cMyBP-C and fsMyBP-C N-terminal fragments activate force development at higher 
Ca2+levels. cMyBP-C is known to activate the thin filament13,16,23 and thus promote Ca2+-sensitivity and 
submaximal force development24 (Supplemental Figure S1D). To determine whether ssMyBP-C and fsMyBP-C 
also affect force development at the muscle fiber level, we applied N-terminal MyBP-C fragments to a force-AT-
Pase assay from pCa 6–4.5. The force-ATPase assay combines isometric force measurements with Ca2+ (pCa), 
myosin ATPase activity, and stiffness relationships (Fig. 1 and Supplemental Figure S1E and F). In this assay, 
permeabilized rat papillary muscle fibers were attached to aluminum t-clips. Each fiber bundle was then hung 
between a force transducer and a length-controller, followed by incubation with vehicle control or one of three 
experimental groups: 10 μM ssC1C2, fsC1C2, or C0C2. Unlike permeabilized myocytes, these thick bundles of 
papillary muscle fibers necessitated the use of high concentrations (10 µM) of fragments because of the higher 
myosin concentration. The presence of 10 µM exogenous N-terminal fragments had no significant differential 
effects on force or fiber stiffness at maximal Ca2+ levels (pCa 4.5) (Supplemental Figure S1D and E). Interestingly, 
exogenous C0C2 and fsC1C2 both increased Ca2+-sensitivity of force development (Fig. 1C and D), and ssC1C2 
appeared to trend towards increasing Ca2+ sensitivity within the Ca2+ range tested. C0C2 and fsC1C2 increase in 
Ca2+-sensitivity also resulted in increased submaximal force generation (Supplemental Figure S1D), suggesting 
that these isoforms regulate some aspect of myosin-actin interaction.
To determine the mechanism by which each isoform increased Ca2+-sensitivity, we analyzed the rate of ten-
sion redevelopment (ktr), which is an estimation of both thin filament activation and cross-bridge cycling kinetics 
(Fig. 1E). To measure ktr, we applied a rapid release-and-restretch maneuver of the muscle fiber. During this 
maneuver, cross-bridges within the sarcomere are mechanically detached by rapidly shortening and immediately 
restretching the muscle fibers to their initial resting sarcomere length. Tension is allowed to redevelop in the 
presence of N-terminal fragments, and the timecourse of the fit of the tension redevelopment curve estimates 
thin filament activation and cross-bridge cycling kinetics. These experiments were conducted at submaximal 
pCa 6 (Fig. 1F and Supplemental Figure S1G) and maximal pCa 4.5 (Supplemental Figure S1H) calcium levels 
to determine the effects of each fragment on ktr at submaximal and maximal activation levels. While no change 
was observed in ktr at maximal activation (pCa 4.5), we show that fsC1C2 and C0C2 increased ktr relative to 
controls at submaximal activation levels (pCa 6) (Fig. 1F), suggesting that these fragments promote thin filament 
activation and/or cross-bridge cycling to regulate Ca2+-sensitivity (Fig. 1D). This data correlates with an increase 
in submaximal force observed when fibers were incubated with fsC1C2 and C0C2 (Supplemental Figure S1D). 
While ssC1C2 trended towards increased ktr (Fig. 1D and F), its effect was not statistically significant from that 
of controls, suggesting that ssC1C2 may not regulate contraction at all within this range (pCa 6–4.5) and that the 
roles of different MyBP-C isoforms are Ca2+-dependent. This result called for functional assays with increased 
sensitivity to determine if MyBP-C regulates contraction at even lower Ca2+ levels. Therefore, we utilized in vitro 
motility assays to probe MyBP-C function from pCa 9 to pCa 4.
MyBP-C N-terminal fragments differentially activate and inhibit thin filament motility in a 
Ca2+-dependent manner. The N-terminal region of cMyBP-C sensitizes thin filaments to Ca2+ 13, but 
it slows thin filament sliding velocities when the thin filament is fully activated14. To investigate how skele-
tal MyBP-C isoforms modulate contraction at low Ca2+ levels compared to maximal Ca2+ levels, we applied 
www.nature.com/scientificreports/
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our N-terminal fragments to in vitro motility assays. The in vitro motility assay was used to characterize the 
Ca2+-dependent motion of mouse cardiac native thin filaments (NTF) over a bed of mouse ventricular myosin 
in the presence of ssC1C2, fsC1C2, and C0C2 fragments (Fig. 2). Thin filament motion was measured as the 
product of the fraction of moving filaments and their sliding velocities, which is an estimate of Ca2+-dependent 
thin filament activation and actomyosin contractility (Supplemental Figure S2). By plotting velocity x fraction 
of moving filaments, we were able to evaluate the impact of the N-terminal fragments (0.25 µM) on both thin 
filament activation at low calcium levels and actomyosin contractility once fully calcium activated. The con-
centration of monomeric myosin incubated in each flow cell was 100 µg/ml, or 217 nM25. Addition of 0.25 µM 
MyBP-C fragments allowed for examination of the effects at an approximate 1:1 ratio to myosin. As expected, 
C0C2 sensitized native thin filament motility at low calcium concentrations (pCa 9–7) and slowed thin filament 
velocities by 43% at high calcium, pCa 4. At the same 0.25 µM fragment concentration, both fsC1C2 and ssC1C2 
sensitized native thin filaments to calcium with ssC1C2, showing activation potency equal to that of C0C2 at pCa 
9–7 (Fig. 2A and D). Indeed, this demonstrates that ssC1C2 does regulate contraction, albeit at very low Ca2+ lev-
els. In contrast, fsC1C2 had only minimal activation capacity at low Ca2+ (pCa 7), whereas fsC1C2 mainly acted 
to inhibit NTF velocities to the degree equal to that of C0C2 (Fig. 2B and E). In stark contrast, the ssC1C2 frag-
ment only modestly regulated NTF sliding at high Ca2+ levels (Fig. 2C and F). These differences were observed 
over a range of fragment concentrations (0–2.0 μM) (Fig. 2D–F) probed in a relaxed state at pCa 9, at the cusp 
of physiological activation at pCa 6.75, and at maximal activation at pCa 4. These results clearly demonstrate 
the calcium-dependent manner in which each isoform regulates motility. For example, at pCa 9, fsC1C2 shows 
little capacity to activate NTFs across all fragment concentrations when compared to C0C2 and ssC1C2. At the 
other extreme, ssC1C2 was not as effective in inhibiting NTF sliding velocity at any pCa value tested (Fig. 2F). 
The motility data demonstrate that each fragment may have evolved to operate over niche ranges of Ca2+ to 
match their respective repertoire of contractile regulation. To illustrate this point, ssC1C2 and C0C2 activate NTF 
sliding velocities at pCa 9-7, while fsC1C2 and C0C2 inhibit NTF sliding velocities at pCa 6-4. These functional 
results suggest that MyBP-C isoforms share similarities in regulatory function. Furthermore, these similarities 
depend on the [Ca2+] and are thus associated with distinct stages of contraction.
Figure 2. In vitro motility assays demonstrate MyBP-C regulation by promoting and inhibiting motility 
of native thin filaments (NTFs) at low and high Ca2+, respectively. (A–C) Control NTFs (grey line) show a 
sigmoidal increase in activation in response to increasing calcium levels. C0C2, fsC1C2, and ssC1C2 (0.25 µM) 
all shift this response to the left, indicating an increased activation effect at lower Ca2+ levels. (A) C0C2 activates 
NTF sliding velocities at both low Ca2+ levels and inhibits NTF motility at high Ca2+ levels. (B) fsC1C2 is unable 
to activate NTF motility at low Ca2+ levels, but inhibits NTF motility at higher Ca2+ levels. (C) Conversely, 
ssC1C2 activates NTF motility at low Ca2+ levels, but lacks the capacity to limit NTF motility at high Ca2+ 
levels. Effects of MyBP-C N-termini varied, depending on concentration, as demonstrated by dose-dependent 
responses of C0C2, fsC1C2, and ssC1C2 on NTF motility at (D) pCa 9 (E) pCa 6.75 and (F) pCa 5. Graphs 
represented as mean ± SEM.
www.nature.com/scientificreports/
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MyBP-C N-termini activate thin filaments by binding to F-actin and shifting tropomyosin. We 
have previously shown that binding of cMyBP-C N-terminal fragments (C0C2, C0C3) to thin filaments, in the 
absence of Ca2+, shifts tropomyosin to the “closed” position, which favors weak cross-bridge formation13. We 
hypothesized that binding of the skeletal MyBP-C isoforms to thin filaments might have a similar impact. To 
test this hypothesis, reconstituted thin filaments (composed of actin (A), tropomyosin (Tm), and the troponin 
(Tn) complex) were decorated with MyBP-C N-terminal fragments (ssC1C2, fsC1C2 and C0C2) at low Ca2+ and 
imaged by negative staining EM (Fig. 3A–D). An increase in filament diameter was observed in the presence of 
each MyBP-C N-terminal fragment, demonstrating the ability of each one to bind to the thin filament (Fig. 3A–D, 
Supplemental Table S3).
Next, 3D reconstructions were computed from these images to visualize whether binding of the different 
MyBP-C isoforms caused any shift in tropomyosin position (Fig. 4). To assess this, the positions of tropomyosin 
in the known blocked and closed positions were superimposed on the reconstructions (red and green helices, 
respectively; Fig. 4A–D). Results showed that all three MyBP-C fragments had shifted tropomyosin from the 
blocked position towards the closed position, as induced by Ca2+ 13,26. C0C2 had the greatest effect, moving Tm 
significantly beyond the closed position (Fig. 4D). fsC1C2 shifted Tm as far as the closed position, while ssC1C2 
was in between (Fig. 4B,C). These differences could be clearly illustrated when reconstructions of each of the 
MyBP-C-decorated filaments were superimposed on the low Ca2+ control filament and viewed either in surface 
view (Fig. 4E–H) or as cross sections (Fig. 4I–O). The greater ability of C0C2 and ssC1C2 to displace Tm suggests 
that they would be more potent activators of thin filaments at low Ca2+ levels than fsC1C2, underscoring the 
Ca2+-dependent manner in which MyBP-C isoforms differentially regulate contraction. This trend is consistent 
with motility data that demonstrated ssC1C2 and C0C2 activate filament sliding at low (pCa 9) Ca2+ levels, while 
fsC1C2 only activated sliding at intermediate Ca2+ levels (pCa 7) (Fig. 2). The different effects of each isoform 
on Tm shift strongly suggest that thin filament activation is one mechanism by which MyBP-C isoforms regulate 
contraction at low Ca2+.
Steady-state thin filament activation may translate to prolonged dynamic relaxation kinet-
ics. Previously, thin filament activation by MyBP-C was postulated to prolong relaxation kinetics by promot-
ing the duration of attached cross-bridges22. The differential thin filament activation capacity of each MyBP-C 
isoform regulates contraction, but may also impact relaxation. Unloaded cardiomyocyte mechanics were utilized 
to provide contraction-relaxation velocities. These are readouts of actomyosin contractility and, hence, a direct 
comparison with the in vitro motility studies. The velocity:pCa results from both model systems can be used to 
characterize changes in Ca2+ sensitivity as a result of the MyBP-C fragments and suggest potential changes in 
relaxation potential. Therefore, we hypothesized that the observed changes in steady-state regulation by MyBP-C 
isoforms allow MyBP-C to regulate dynamic relaxation kinetics, as well. To test this hypothesis, our steady-state 
experiments examined MyBP-C isoform-specific modulation of force-pCa in permeabilized fibers and thin fila-
ment activation/inhibition of NTF motility (Figs 1–4, Table 1). To test if MyBP-C isoforms could alter relaxation 
kinetics during dynamic contraction, we utilized intact, isolated cardiomyocytes, and they were allowed to freely 
contract and relax. We analyzed unloaded shortening kinetics of electrically stimulated (2.0 ms, 1 Hz, 20 V) adult 
rat ventricular myocytes (ARVM) infected with adenoviral constructs overexpressing full-length, Myc-tagged 
ssMyBP-C, fsMyBP-C, or cMyBP-C in culture for 48 hours. Full-length MyBP-C isoforms were used because 
abnormal localization and function of N-terminal fragments would result from the absence of the C-terminal 
region27, even though the N-terminal region localizes to the A-band24. Immunofluorescence imaging revealed 
that adenoviral-mediated MyBP-C isoforms expressed and localized properly to the sarcomere A-band where 
myosin thick filaments reside (Fig. 5A and Supplemental Figure S3). Densitometry analysis of Western blots 
also revealed partial replacement of endogenous cMyBP-C with adenoviral-mediated constructs (Supplemental 
Figure S4A and B). Unloaded shortening experiments demonstrated that cMyBP-C prolonged relaxation kinetics 
Figure 3. Electron microscopy (EM) shows binding of ssC1C2, fsC1C2, and C0C2 to reconstituted thin 
filaments. (A) Control thin filaments reconstituted from F-actin, tropomyosin, and troponin at a molar ratio of 
7:2:2 in low Ca2+ buffer and imaged by negative staining. (B–D) Reconstituted thin filaments decorated with (B) 
ssC1C2 (C) fsC1C2 and (D) C0C2. Binding of these N-terminal fragments is evident both from the images and 
from an increase in filament diameter (Supplemental Table S3).
www.nature.com/scientificreports/
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relative to ssMyBP-C and fsMyBP-C, as determined by time to percent baseline, i.e., how fast the cell returned 
to resting sarcomere length (SL) and tau, which is the relaxation constant based on a fit of the relaxation trace 
(Fig. 5B and C). In combination with our steady-state observations, greater thin filament activation has been 
suggested to prolong relaxation22, which explains the effect cMyBP-C had on our ARVM system.
To determine whether the greater capacity of cMyBP-C to activate the thin filament also explains its regulation 
of relaxation kinetics during contraction, we utilized an online muscle simulator (OMS) that simulates unloaded 
shortening of a single cardiomyocyte28. By adjusting parameters that accounted solely for differential capacity to 
activate the thin filament (kon), we could use the OMS for specific modelling of steady-state parameters that affect 
unloaded shortening (Fig. 5D and Supplemental Table S4). The resulting in silico unloaded shortening traces 
recapitulated in vitro composite traces and data (Fig. 5B–D), suggesting that greater thin filament activation by 
cMyBP-C regulates relaxation. Collectively, these data demonstrate that regulation of steady-state contraction by 
different MyBP-C isoforms can contribute to relaxation kinetics in dynamic contraction.
Discussion
Contractile proteins often have cardiac and skeletal isoforms29, and MyBP-C is no exception. Unique expres-
sion profiles demonstrate that these isoforms can be co-expressed in health and disease5,6, underscoring the 
Figure 4. 3D reconstruction of thin filaments demonstrates MyBP-C N-termini shift of tropomyosin in the 
absence of Ca2+. (A) Reconstruction of reconstituted thin filament (F-actin, tropomyosin, troponin). Actin 
atomic structure (yellow ribbon) has been fitted into the reconstruction (grey envelope). Red and green helices 
represent Tm in the known blocked and closed positions on the thin filament, respectively. In this control 
filament, at low Ca2+, Tm occupies the blocked position (grey cylinder enclosing red Tm helix). Tn is averaged 
out as it does not follow the helical symmetry of actin used to carry out the reconstructions. The addition of 
(B) ssC1C2, (C) fsC1C2, and (D) C0C2 causes a shift in Tm azimuth towards the closed position, with C0C2 
causing the largest shift and fsC1C2 the smallest. These variable shifts are further revealed when each decorated 
reconstruction is superimposed on the actin:tropomyosin:troponin control, both in surface view (E–H) and in 
cross-sectional views of the reconstructions (I–O) (cf. ref.14). Actin subdomains 1–4 are marked in I. Red arrows 
indicate Tm in blocked position in low Ca2+ control filament; green arrows show shifted position of Tm in low 
Ca2+ decorated filaments.
www.nature.com/scientificreports/
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need to determine functional differences and similarities among all three MyBP-C isoforms. Additionally, as 
new disease-causing mutations in the two skeletal MyBP-C isoforms are discovered9–11, studies that provide 
insight into the function of ssMyBP-C and fsMyBP-C are becoming increasingly relevant7,30. Indeed, our results 
do demonstrate clear differential functional roles for ssMyBP-C, fsMyBP-C, and cMyBP-C in regulating muscle 
contraction.
One key finding was that MyBP-C isoforms activate the thin filament within functional Ca2+ niches. Here, 
we demonstrate that ssMyBP-C promotes NTF sliding at low [Ca2+], and fsMyBP-C inhibits NTF sliding at high 
[Ca2+], while cMyBP-C has the capacity to regulate both at both low and high calcium. Furthermore, the capacity 
of each MyBP-C isoform to regulate within a particular range of [Ca2+] is dependent on the ability of each to bind 
to, and activate the thin filament. At low [Ca2+], ssC1C2 and C0C2 shifted Tm beyond the ‘closed’ position, which 
would be expected to activate the thin filament by partially exposing the myosin-binding site on actin (Fig. 4F–
H)13. This increased ability to activate the thin filament correlated with increased NTF sliding velocities at low 
[Ca2+] (pCa 9), but had no effect at high [Ca2+]. Thus, MyBP-C appears to have a key role in initiating contrac-
tion. Conversely, fsC1C2 activation of sliding did not occur until intermediate Ca2+ levels (pCa 7). Where fsC1C2 
exhibited marked regulation was its ability to reduce NTF sliding velocities at high [Ca2+] to a degree equal to 
that of C0C2. Correspondingly, fiber studies demonstrated that fsC1C2 and C0C2 enhanced force production 
above pCa 6. In contrast, ssC1C2 did not appear to have a significant regulatory function in the fiber experiments, 
possibly because the lower Ca2+ limit of this assay was pCa 6, and the regulatory capacity of ssC1C2 is limited 
to lower [Ca2+]. Interestingly, when we compared the results of the fiber and motility assays, we concluded that 
fsC1C2 and C0C2 share similarities in contractile regulation at intermediate and high Ca2+ levels (Supplemental 
Figure S1). These isoforms may promote force generation by contributing to the stability and maintenance of 
strongly bound cross-bridges31.
It is important to note that the present studies focus on MyBP-C N-terminal interactions with the thin fil-
ament and do not preclude regulation by MyBP-C through its interactions with myosin. Indeed, MyBP-C may 
form a “C-bridge,” in which full-length MyBP-C binding to the thin filament creates a secondary thick-to-thin 
filament interaction, the functional consequences of which are not well understood. This interaction may allow 
MyBP-C to interact with both actin and the myosin head region. The MyBP-C/actin interaction promotes the “on” 
state of the thin filament (fapp), competing with myosin for an actin-binding site specifically within the C-zone 
and/or placing a load on actin to limit contractility32,33. Alternatively, MyBP-C may place a load on the myosin 
head region, limiting cross-bridge formation by maintaining myosin in its off state (gapp)19. Whether MyBP-C 
binds to the thin or thick filament may depend on the stage of contraction and, by association, the levels of Ca2+ 
in the sarcomere. Recent studies have highlighted Ca2+-dependent regulation by cMyBP-C34,35 and the physiolog-
ical role for MyBP-C in preventing muscle hypercontractility36.
A second key finding was that all MyBP-C isoforms alter thin filament properties to regulate Tm shift on actin. 
Both the binding affinity of MyBP-C to actin and its effects on the thin filament underlie the ability of MyBP-C to 
regulate contraction at various ranges of Ca2+, suggesting, in turn, that MyBP-C may both inhibit and facilitate 
myosin binding. The greater capacity of C0C2 to activate the thin filament and thus enhance Ca2+-sensitivity 
would help maintain actomyosin interactions. Longer actomyosin interactions would explain why relaxation is 
prolonged in cardiomyocytes expressing cMyBP-C, as observed in our test of unloaded myocyte shortening. Thin 
filament activation by cMyBP-C is the strongest of the three isoforms and would prevent dissociation of myosin 
from actin, despite the decrease in intracellular Ca2+. While our studies were not conducted in disease models, 
unregulated increases in Ca2+-sensitivity result in incomplete relaxation and diastolic dysfunction, which is a 
common phenotype in HCM37, which is reported to be caused by mutations in cMyBP-C. An alternate possi-
ble explanation for the observed relaxation regulation by cMyBP-C lies in its C0 domain. In our studies, both 
fsMyBP-C and cMyBP-C similarly regulate contraction at high Ca2+ (Fig. 1), suggesting that the C0 domain may 
not be necessary for regulating contraction, but rather may primarily function as a regulator of relaxation.
Some limitations of our study should be noted. We have focused on the functional effects of the N-terminal 
region of slow-skeletal, fast-skeletal, and cardiac MyBP-C in the context of cardiac muscle contraction. The use of 
N-terminal fragments in our experiments enables direct comparison with research in the field13,23,38, but MyBP-C 
N-termini do not exist in isolation. The N-terminal region is part of a much larger protein; the C-terminus of 
which is responsible for anchoring MyBP-C within the C-zone of the sarcomere39,40. Therefore, recombinant 
MyBP-C proteins may elicit effects outside the C-zone, potentially exaggerating the functional effects of MyBP-C. 
Furthermore, since the predominant myosin isoforms in human hearts are different from those of mouse, com-
parisons with, or conclusions drawn from, previous studies will be correspondingly affected. Importantly, our 
Experimental Assay System Concentration of N’ fragment Results at lower Ca2+ (pCa 9–7)
Results at higher Ca2+ 
(pCa 6–4.5)
Force-ATPase Adult Rat Papillary Muscle Fiber Bundles 10 µM N/A
C0C2 and fsC1C2 
increased force, Ca2+ 
sensitivity, ktr
In vitro Motility Assays Mouse myosin and Native Thin Filaments 0.25 µM 0.10–2.0 µM C0C2 and ssC1C2 activate NTF motility C0C2 and fsC1C2 inhibit NTF motility
3D reconstruction of EM images Reconstituted thin filament 6 µM Graded shifts in tropomyosin position (C0C2 > ssC1C2 > fsC1C2) N/A
Table 1. Summary of steady-state experimental results. The table summarizes all steady-state experiments 
performed in the present studies, experimental systems and concentration of the MyBP-C fragments used. 
Results are summarized at lower and higher Ca2+ concentration.
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focus on MyBP-C and the thin filament does not preclude the effect of MyBP-C on myosin, and further studies 
may elucidate how these myofilament proteins affect one another.
In conclusion, our comprehensive experimental approach highlights the nuanced differences between 
MyBP-C isoforms in the context of regulating the contraction of striated muscles. Specifically, cMyBP-C regu-
lation extends over the full range of Ca2+ in contrast to the slow- and fast-skeletal isoforms, which regulate con-
traction at lower and higher ranges of Ca2+, respectively. We postulate that Ca2+-range specificity enables cardiac 
MyBP-C to function over a wide range of Ca2+ on a beat-to-beat basis. In contrast, different skeletal muscles 
contract and relax with variable frequency. Thus, various slow-twitch and fast-twitch skeletal muscles may be 
fine-tuned for specific functions by expressing different amounts of slow- and fast-skeletal MyBP-C. In contrast, 
the function of cMyBP-C is highly tunable via post-translational modification19 which modulates its interactions 
with actin and myosin. Phosphorylation sites on ssMyBP-C suggest that skeletal isoforms may be similarly regu-
lated21, which will be addressed in future studies focusing on the skeletal muscle system.
Figure 5. Greater activation of thin filament results in prolonged diastole. (A) To determine how each isoform 
regulates dynamic contraction, full-length MyBP-C adult rat ventricular myocytes (ARVM) were infected 
with adenoviral constructs (MOI 1000) overexpressing full-length, cMyc-tagged slow-skeletal, fast-skeletal, or 
cardiac MyBP-C, followed by 48 h culture. (B) Immunofluorescence (IF) imaging demonstrates localization of 
adenoviral-mediated expression of MyBP-C isoforms (green) within the sarcomere, as delineated by α-actinin 
(red). (C,D) Unloaded shortening was measured by changes in sarcomere length (SL) during dynamic 
contraction and relaxation (ARVM paced at 1 Hz, 20 V, 2 ms). (C) Relaxation kinetics was measured by time 
to % baseline, how fast the cell returns to 10, 50, and 90% of resting SL, and (D) relaxation constant tau, a 
logarithmic fit of the relaxation curve. (E) Changes in relaxation kinetics were evident by combined traces, 
and in silico simulations demonstrate that greater thin filament activation can contribute to relaxation kinetics. 
Graphs represented as mean ± SEM, *p < 0.05 vs. uninfected controls, #p < 0.05 vs. cMyBP-C.
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Experimental Methods
Expression and Purification of Recombinant MyBP-C proteins. Recombinant proteins represent-
ing the N-terminal domains up to the C2 domain of slow-skeletal, fast-skeletal, and cardiac isoforms (ssC1C2, 
fsC1C2, and C0C2, respectively) were generated, purified, and analyzed with SDS-PAGE41 (Fig. 1). Each MyBP-C 
isoform was expressed using a pET28 expression system (Millipore 70777) in E. coli and included an N-terminal 
His-tag. Protein expression in BL21 was induced by IPTG and purified through a nickel-nitrilotriacetic acid 
affinity column in which eluted fractions were combined and dialyzed in PBS. Recombinant proteins were used 
in all following steady-state biophysical studies to determine the functional differences among the slow-skeletal, 
fast-skeletal, and cardiac isoforms of MyBP-C.
Muscle Fiber Bundle Preparation. All experiments in the present study were performed in accordance 
with the National Institutes of Health Guidelines for the Care and Use of Animals for Experimental Procedures. 
The experimental protocols were approved by the Institutional Animal Care and Use Committee protocol at 
Loyola University Chicago, Maywood, IL. In a sterile environment, male Sprague-Dawley rats (250 g, Harlan) 
were euthanized using Beuthanasia-D solution, and the whole heart was rapidly excised and submitted to retro-
grade perfusion with Krebs-Henseleit Buffer (KHB) via proximal aorta. The heart was cut to carefully expose the 
papillary muscles in the left ventricle. Papillary muscles were carefully excised under a dissecting scope (Zeiss 
Discover.V8 Stereo, PlanAPO S 0.63 × FWD 81 mm) and permeabilized overnight in 1% Triton X-100 (Sigma) 
in mounting relaxing solution (6.3 mM ATP, 6.48 mM Mg Cl2, 10 mM EGTA, 10 mM Na2CrP, 49.76 mM Kprop, 
100 mM BES, pH 7) at 4 °C, removing cell membrane and membrane-bound proteins. After overnight permea-
bilization, papillary muscles were further trimmed into fiber bundles approximately 1 mm in length under the 
dissecting microscope. Straight and parallel fiber bundles were selected based on uniformity and attached at 
each end with aluminum t-clips. Images were taken under the dissecting scope using an attached digital cam-
era (Canon EOS Rebel T3i). Each fiber bundle was gently cleansed by transferring between a series of 4 washes 
containing fresh relaxing solution on ice and used within 12 hours. The t-clipped fibers were attached to a force 
transducer (BAM21-LC; World Precision Instruments, Sarasota, FL) and high-speed length controller (Aurora 
Scientific, Inc.). Muscle dimensions (cross-sectional area, length, and volume) were determined using an ocular 
micrometer mounted in the dissection microscope (resolution, ~10 μm). These muscle dimensions were used to 
normalize contractile force, sarcomere length (SL) and ATPase activity. SL was measured in passive relaxed con-
dition by laser diffraction as previously described42, adjusted to, and maintained at 2.0 μm. Briefly, a helium-neon 
laser beam was directed through the isolated muscle fiber bundle, in which muscle striation pattern diffracts the 
laser beam into a diffraction pattern. The striations of the muscle fiber bundle act as a grating, with known angles 
of diffraction, and the projected pattern can therefore be used to measure average SL.
Incubating with MyBP-C N-termini. The permeabilized fibers were incubated with 10 μM of the ssC1C2, 
fsC1C2, and C0C2 recombinant proteins or unincubated for 3 minutes in relaxing solution, followed by 3 min 
in preactivating solution, before measuring force in activating solution. Activating solution contained 20 mM 
Ca2+-EGTA, 1.55 mM potassium propionate, 6.59 mM MgCl2, 100 mM N,N-bis (2-hydroxyethyl) taurine; 
N,N-Bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid, 5 mM sodium azide, 1 mM DTT, 10 mM phosphoe-
nolpyruvate, 0.01 mM oligomycin, 0.1 mM PMSF, 0.02 mM A2P5, and a commercial protease inhibitor cocktail 
(Sigma). Relaxing solution was the same as activating solution, but contained 20 mM EGTA, 21.2 mM potassium 
propionate, 7.11 mM MgCl2, and no calcium. Preactivating solution was the same as the activating solution, but 
contained 0.5 mM EGTA, 19.5 mM 1,6-diaminohexane-N,N,N,N’-tetraacetic acid, 21.8 mM potassium propion-
ate, and no calcium. All solutions contained 0.5 mg/ml pyruvate kinase and 0.05 mg/ml lactate dehydrogenase 
(Sigma) and had an ionic strength of 180 mM, 5 mM MgATP, and 1 mM free magnesium. Recombinant proteins 
were present in relaxing and preactivation solutions for subsequent measurements. The activation solution did 
not have recombinant proteins present to avoid potential complications with changes in Ca2+ levels. Isometric 
tension and ATPase activity were measured at various levels of Ca2+ activation as previously described43. Briefly, 
the isolated muscle was exposed to a range of calcium solutions obtained by proportional mixing of activat-
ing and relaxing solutions. The force generated and ATP consumed were measured simultaneously during the 
contraction.
Force-pCa, Force-ATPase, and rate of tension redevelopment. Force-pCa relationship was deter-
mined by titrating the activation and relaxing solutions44. Maximal isometric tension was measured at 100% 
activation solution, followed by sequential washes in relaxing and preactivating solutions for 5 minutes each. 
However, subsequent measurements of isometric tension occurred in solutions titrated with decreasing ratio 
of activation-to-relaxation solutions, which corresponded to pCa values of 4.50, 5.11, 5.42, 5.61, 5.77, 6.00, and 
10.00, respectively, as determined by the Fabiato program45. The integrity of the fibers was tested afterwards by 
measuring maximal tension after the experiment. Any fibers that did not maintain 80%, or greater, maximal 
tension were excluded from analysis. Force-ATPase relationship was determined using an optical absorbance 
enzyme assay44. Briefly, ATP consumption was determined by measuring the absorbance of UV light at a wave-
length of 340 nm. The hydrolysis ATP to ADP and inorganic phosphate is stoichiometrically coupled to the oxi-
dation of NADH to NAD+. This oxidization reaction was catalyzed by pyruvate kinase and lactate dehydrogenase 
in our activating solutions. NADH, but not NAD+, absorbs light specifically at 340 nm. A series of 50 nl of 10 mM 
ADP was injected into the measuring chamber. Each injection of ADP induced a rapid reduction in fluores-
cence and allowed the calculation of the rate of ATP consumption, as determined by measuring the fluorescent 
decay rate at 340 nm. After completion of the Force-ATPase assay, muscles underwent a rapid release-restretch 
maneuver in order to break previously formed cross-bridges and allow cross-bridges to reform. The rate constant 
of tension redevelopment (ktr) was then measured at maximal activation, as previously described46. Force-pCa 
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTS |  (2018) 8:2604  | DOI:10.1038/s41598-018-21053-1
and Force-ATPase relationships were fitted with a modified Hill equation. Stiffness and tension costs were fitted 
linearly to the Force-stiffness and Force-ATPase data, respectively.
In vitro Motility Assay. For in vitro motility assays, actin filament movements over a cardiac myosin-coated 
flow cell were observed by epifluorescence microscopy13. The experimental flow cell was maintained at 22 °C. 
Briefly, cardiac myosin from mice (100 µg/mL) were incubated in a nitrocellulose-coated flow cell (2 minutes), 
followed by blocking with two aliquots of BSA (1 mg/mL) in actin buffer (AB: 25 mM KCl, 1 mM EGTA, 10 mM 
DTT, 25 mM imidazole, 4 mM MgCl2, pH 7.4). One μΜ of unlabeled native thin filaments (NTFs) in AB was 
added to the flow cell for 1 minute. To eliminate myosin-bound actin, the flow cell was washed twice with 1 mM 
ATP in AB, followed by two washes with AB alone. Two aliquots of tetramethyl-rhodamine-phalloidin-labeled 
NTFs were added to the flow cell for 1 minute and rinsed three times with just AB. Finally, to observe NTF 
movement, we added motility buffer (MB: actin buffer with 100 μΜ ATP, 0.5% methyl cellulose, and CaCl2) to 
the flow cell. The motility buffer contained a range of calcium concentrations, presented as pCa (−log [Ca2+]), 
and ranged from pCa 4–9, as determined using MaxChelator software47. We used a Lumen 200 W metal arc 
lamp (Prior Scientific), Nikon Eclipse TiU microscope with Plan Apo objective (100×, 1.35 n.a.) and Mega Z 
10 bit digital camera (Stanford Photonics) for fluorescent excitation of labeled NTFs and image acquisition, 
respectively. Images were acquired using Piper software at 10 frame/s without pixel binning (95 nm/pixel) and 
down-sampled to 2 frames/s using ImageJ 1.43 u (NIH). We analyzed the images for velocity of individual NTFs 
and percentage of mobile NTFs in each movie using DiaTrack 3.03 software (Semasopht). Data were collected 
as the velocity of moving and percentage of moving filaments from individual movies (Supplemental Figure S2). 
Data are presented as mean velocity × fraction of moving NTFs ± SEM from triplicate independent experiments 
(Fig. 2). These data were plotted against pCa and fitted to a sigmoidal dose-response curve, with pCa50 represent-
ing changes in calcium sensitivity.
Electron microscopy. For control thin filaments in low Ca2+ condition, F-actin, tropomyosin, and troponin 
were mixed at a molar ratio of 7:2:2 in buffer48 (100 mM KAcetate, 2 mM MgCl2, 0.2 mM EGTA, 1 mM DTT, 
10 mM MOPS, pH 7.0), as reported in previous thin filament studies13,16,49. The two-fold molar excess of Tm and 
Tn was used to maintain binding of these regulatory proteins at the low protein concentrations needed for EM. 
These reconstituted thin filaments and F-actin were then decorated with the recombinant N-terminal MyBP-C 
proteins. Thin filaments at a concentration of 2 µM actin were mixed with 6 µM ssC1C2, fsC1C2, or C0C2 (i.e., a 
1:3 ratio of actin subunits: C1C2 or C0C2) under the same buffer conditions. After mixing, solutions were incu-
bated at room temperature for 30 min. Five µl aliquots were then applied to EM grids coated with thin carbon 
supported by a holey carbon film and then negatively stained with 1% uranyl acetate50. Dried grids were observed 
in a Philips CM120 electron microscope (FEI, Hillsboro, OR) at 80 KV under low-dose conditions. Images of fil-
aments were acquired at a pixel size of 0.35 nm, using a 2 K x 2 K CCD camera (F224HD, TVIPS GmbH, Gauting, 
Germany).
3D Reconstruction. Long and relatively straight filaments were selected for 3D reconstruction and 
straightened with ImageJ (NIH), as previously described13. Straightened filaments were converted to SPIDER 
format (EM2EM; Image Science and Imperial College, London, UK) and cut into segments in SPIDER (v11.2, 
Wadsworth Center, Albany, NY). Iterative Helical Real-Space Reconstruction (IHRSR) was carried out in 
SPIDER51, using an F-actin model as an initial reference. The process was repeated for 20 rounds, with conver-
gence usually occurring within 10 rounds. UCSF Chimera52 was used for visualization, analysis, and atomic fitting 
of 3D volumes.
Comparison and Atomic Fitting of Reconstructions. Accurate matching of reconstructions to each 
other was essential to determine whether MyBP-C N-termini resulted in tropomyosin movement. This was 
achieved using ChimeraX, as described previously13. Reconstructions were fitted with atomic models of F-actin 
or F-actin-tropomyosin using the ChimeraX “fit in map” tool13.
Computational modeling. We used a computational model that had previously been demonstrated to 
predict changes in unloaded shortening of individual cardiomyocytes53. The myofilament model accounts for 
length-dependent activation and strain-dependent XB kinetics54,55. Since our goal was to model unloaded short-
ening, in which individual cardiomyocytes are isolated, components accounting for force55,56 were set to zero. 
Computer modelling accounts for differential capacity of MyBP-C to activate the thin filament, defined as kon, or 
the rate of tropomyosin shift from blocked to closed position (see Supplemental Table S4).
Isolation of adult rat cardiomyocytes. Cardiomyocytes from adult Sprague-Dawley rats (250 g) were 
isolated as previously described27. After isolation, cardiomyocytes were gradually switched into plating media, 
which contained HMEM supplemented with 100 U/mL penicillin/streptomycin (pen/strep), 10% fetal bovine 
serum, and 10 mM BDM. For functional measurements, cardiomyocytes were plated on laminin-coated 25 mm 
coverslips. For protein analysis, cells were directly plated onto laminin-coated 35 mm circular dishes. After 1-hour 
incubation, plating media were removed, and culture media were added. Culture media consisted of HMEM, 
supplemented with 0.1% BSA, 100UmL pen/strep, 2 mM glucose, 10 mM BDM, and 5ug/mL insulin/transferrin/
selenium (ITS) supplement. Cells were kept in a 2% CO2 incubator to maintain pH of 7.0 and maintained for 
48 hours.
Adenovirus Infection and Cell Culture. Commercially purchased slow- and fast-skeletal MyBP-C clones 
from Origene (NM_175418.3 and NM_004533, Rockville, MD) were used to construct the adenoviruses overex-
pressing skeletal isoforms of MyBP-C. cMyBP-C adenoviral vectors were generated by the core facilities at Loyola 
www.nature.com/scientificreports/
1 1SCIENTIFIC REPORTS |  (2018) 8:2604  | DOI:10.1038/s41598-018-21053-1
University Chicago. Adenoviral constructs were created by cotransfection of MyBP-C cDNA into DH5α E. coli. 
Adenoviruses containing slow, fast, or cardiac MyBP-C included a CMV promoter and c-Myc tag to distinguish 
between endogenous and adenovirus-mediated MyBP-C protein expression. Uninfected cells and c-Myc-tagged 
cMyBP-C-overexpressing cells were used as experimental controls. Adenoviral constructs overexpressing slow, 
fast, and cardiac MyBP-C (Multiplicity of Infection MOI: 1000) were added to the culture media 1 hour after incu-
bation and allowed to infect cardiomyocytes for 24 hours. Culture media were changed after 24 hours, removing 
the adenovirus and waste and replenishing nutrients in the media.
Immunofluorescence Imaging. Cultured adult rat cardiomyocytes were plated on chamber slides 
(Lab-Tek II, Thermo Scientific) for immunofluorescence imaging. After 48 hours in culture, cells were rinsed 
twice with PBS and fixed with cold (4 °C) 4% paraformaldehyde for 3 minutes, followed by 1 minute in ice cold 
(−20 °C) methanol. Cells were then permeabilized in 0.5% Triton X-100 in PBS (20 minutes), 0.1% Triton X-100 
twice (10 minutes), and antigen-retrieval solution (0.1 M glycine, pH 7.4) (30 minutes), followed by rinsing three 
times with PBS. Cells were blocked with 0.1% BSA, 0.1% gelatin, 0.1% Tween-20, and 0.0001% NaN3, followed by 
incubation with primary antibodies for ssMyBP-C (ProSci 6679), fsMyBP-C (ProSci 5651), rabbit c-Myc (1:500 
Roche) and mouse α-actinin (1:500 Sigma) overnight. After rinsing with PBS, corresponding secondary antibod-
ies (AlexaFluor rabbit 488 at 1:50 dilution and mouse 568 at 1:50 dilution) were added for 1 hour at room temper-
ature, rinsed, and coverslipped with VectaShield mounting medium (Vector Labs H-1500 10mUL 1.5ug/mL) for 
imaging with confocal microscopy. Images were taken using a Leica TCS SP5 and processed using ImageJ (NIH).
Western blot analyses. Detection of endogenous and de novo MyBP-C protein in cardiomyocytes was 
determined by immunoblotting. Adenovirus-infected cardiomyocytes were rinsed with sterile PBS to remove 
culture media, followed by the addition of 60 uL of urea buffer. Cardiomyocytes were scraped off using a cell lifter 
(Fisher Scientific) and pipetted into 0.6 mL tubes. Twenty-five uL of 4 × loading dye (0.4% bromophenol blue, 
10% ß-mercaptoethanol) were then added. Samples were heated at 100 °C for 5 minutes, separated by gel elec-
trophoresis in 10% SDS-PAGE gels, and blotted onto nitrocellulose membrane at 300 mA for 3 hours. Detection 
of protein was determined by using antibodies for c-Myc, ssMyBP-C, fsMyBP-C, and cMyBP-C (Sigma C3956, 
ProSci 6679, ProSci 5651, and Santa Cruz sc-137180, respectively)6 (Supplemental Figure S4). Quantification of 
replacement levels was determined by densitometry analysis normalized to ß-actin loading controls, using ImageJ 
(NIH). Replacement levels were calculated by signal of cMyc/(cMyc + cMyBP-C), as previously described57.
Unloaded shortening in cultured adult rat ventricular cardiomyocytes. After 48 hours in culture, 
HMEM media were incrementally replaced with Tyrode’s solution (135 mM NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 10 mM d-glucose, and 10 mM HEPES) to limit damage to the cells. Coverslips with attached cardiomyo-
cytes were transferred to a custom stimulation chamber containing platinum electrodes. The chamber was then 
fitted onto a Nikon microscope stage and stimulated (2.0 ms pulse, 1 Hz, and 20 V). Sarcomere length and SL 
shortening were measured by a video-based detection system (Ionoptix, Milton, MA). Analysis of contractile 
function was determined from an average of 10 contractions of individual cardiomyocytes, with 10–20 cardiomy-
ocytes measured per coverslip preparation.
Statistical Analysis. All data are presented as means ± SEM. Data were analyzed using one-way ANOVA 
with a Bonferroni post-test. Statistical significance was set at p < 0.05.
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